New PTSD drug HB-1 heads to phase 2 trial
Symptom relief
Not yet recruiting
This study tests whether a new drug, HB-1, is safe and effective at reducing PTSD symptoms compared to a placebo. It will involve 200 adults aged 18 to 65 with PTSD. The main goal is to see if symptoms improve over 12 weeks using a standard PTSD rating scale.
Phase: PHASE2 • Sponsor: HB BioTech, LLC • Aim: Symptom relief
Last updated Apr 26, 2026 20:00 UTC